Triple therapy for DME better than one

Article

Triple therapy consisting of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation may facilitate early recovery of vision in patients with intractable diabetic macular oedema.

Triple therapy consisting of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation may facilitate early recovery of vision in patients with intractable diabetic macular oedema (DME). These are the recent findings of a study in the October issue of the American Journal of Ophthalmology.

Twenty-four eyes of 24 subjects diagnosed with intractable DME underwent vitrectomy followed by intravitreal triamcinolone acetonide injection and macular laser photocoagulation at one and 14 days after, respectively. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before surgery and three, six and 12 months postoperatively.

The mean logarithm of the minimum angle of resolution BCVA was 0.88±0.37 before surgery, 0.55±0.33 at three months, 0.56±0.27 at six months and 0.48±0.28 at 12 months. Meanwhile, the mean CMTs before and three, six and 12 months after therapy were 514±187 µm, 253±138 µm, 219±95 µm and 197±91 µm, respectively.

The major adverse events after therapy were development of nuclear sclerotic cataracts (eight of 12 phakic eyes) and elevation of intraocular pressure (eight of 24 eyes).

Based on these results, the authors concluded that the triple therapy may facilitate early recovery of vision and may improve the long-term outcomes in some patients with DME refractory to conventional monotherapy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.